Tests atorvastatin with standard drugs in people with pulmonary tuberculosis
Tests atorvastatin at different doses with standard TB drugs in people with lung tuberculosis.
Key facts
- Who runs it
- Obafemi Awolowo University Teaching Hospital
- Where
- Gwagwalada, Ibadan, Ile-Ife, Iwo, Katsina, Keffi, Sokoto, and Zaria, NigeriaSee the 8 sites
- Trial code
- Registry title
- ATORvastatin in Pulmonary TUBerculosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 440 people, planned
- Started
- 3 Jan 2024
- Planned end
- 30 Sept 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atorvastatin 20mg
- Atorvastatin 40mg
- Atorvastatin 60mg
- Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
- Record updated
- 25 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 12 to 65 with lung tuberculosis who have not been treated before and have a positive sputum test. They get standard TB drugs with or without atorvastatin.
- Age
- 12 to 65 years
- Sex
- Men and women
- Disease stage
- Suspected lung tuberculosis with a positive sputum smear for acid-fast bacilli, or a positive Xpert MTB/RIF test (medium or high result, no rifampicin resistance).
- Earlier treatment
- Must not have had TB treatment before (treatment naive).
- Biomarker or test result
- HIV status and blood sugar level must be documented. People with HIV need a CD4 T cell count of at least 100 cells/mm3. Blood tests for liver, kidney, potassium, haemoglobin and platelets must be in the set limits.
Main reasons for not taking part
- Pregnant or breast-feeding
- Weight under 40.0 kg (88 lb)
- TB already known to be resistant to rifampin, isoniazid, pyrazinamide or ethambutol
- Heart disease, cancer or other serious illness
- Cannot take oral medicines
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Individuals must meet all the following inclusion criteria in order to participate in this study:
- Suspected pulmonary tuberculosis plus one or both of the following: a) at least one sputum specimen positive for acid-fast bacilli on smear microscopy OR b) at least one sputum specimen positive for M. tuberculosis by Xpert MTB/RIF testing, with semiquantitative result of 'medium' or 'high' and rifampicin resistance not detected
- Treatment naive
- Age twelve years or older
- A verifiable address or residence location that is readily accessible for visiting, and willingness to inform the study team of any change of address during the treatment and follow-up period
- Documented HIV infection status
- Documented blood sugar level/ Diabetes
- For HIV-positive individuals, CD4 T cell count greater than or equal to 100 cells/mm3 based on testing performed at or within 30 days prior to screening
- Laboratory parameters done at or within 14 days prior to screening:
- Serum or plasma alanine aminotransferase (ALT) less than or equal to 3 times the upper limit of normal
- Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit of normal
- Serum or plasma creatinine level less than or equal to 2 times the upper limit of normal
- Serum or plasma potassium level greater than or equal to 3.5 meq/L
- Hemoglobin level of 7.0 g/dL or greater
- Platelet count of 100,000/mm3 or greater
- For women of childbearing potential, a negative pregnancy test at or within seven (7) days prior to screening
- Written informed consent
Who cannot take part
- Individuals with any of the following exclusion criteria at the time of enrollment or initiation of study drugs will be excluded
- Unable to take oral medications
- Those already on treatment for tuberculosis
- Known allergy or intolerance to any of the study medications
- Individuals will be excluded from enrollment if, at the time of enrollment, their M. tuberculosis isolate is already known to be resistant to any one or more of the following: rifampin, isoniazid, pyrazinamide,or ethambutol,
- .Evidence of clinically significant metabolic or co morbid medical conditions ; malignancy; or other diseases like history of or current cardiovascular disorder such as heart failure, coronary heart disease, arrhythmia
- Screening, baseline, and Week 2 study visit sputum cultures all fail to grow M. tuberculosis
- M. tuberculosis cultured or detected through molecular assays (Cepheid Xpert MTB/RIF or Hain MTBDRplus assays) from sputum obtained around the time of study entry is determined to be resistant to one or more of isoniazid, rifampin, or fluoroquinolones
- Known or family history of bleeding disorders. I. Any renal impairment characterized by serum creatinine clearance of 1.5 x upper limit of normal of the clinical laboratory reference range at screening
- Myositis and or Creatinine phosphokinase three times upper limit of normal K. Other medical conditions, that, in the investigator's judgment, make study participation not in the individual's best interest; Criteria for Exclusion after Enrollment ('Late Exclusion'); Microbiological confirmation of drug-susceptible tuberculosis is not expected always to be available at the time of enrollment. Enrolled individuals who are subsequently determined to meet either of the following criteria will be classified as 'late exclusions' and study treatment will be discontinued:
- Pregnant or breast-feeding
- Weight less than 40.0 kg
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 65 years old?
Where in Nigeria
- University of Abuja Teaching HospitalGwagwalada, NigeriaContact: Alex Akor, MDTaking people
- University College HospitalIbadan, NigeriaContact: Olumide Sogaolu, MDTaking people
- Obafemi Awolowo University Teaching Hospitals ComplexIle-Ife, NigeriaContact: Olufemi Adewole, MDTaking people
- Bowen University Teaching HospitalIwo, NigeriaContact: Abiona Odeyemi, MDTaking people
- Federal Teaching HospitalKatsina, NigeriaContact: Taofeek OloyedeTaking people
- Federal Medical CenterKeffi, NigeriaContact: Modupe Ogunsina, DrTaking people
- Usman Danfodio UniversitySokoto, NigeriaContact: Aminu AbbasTaking people
- National Tuberculosis Reference LaboratoryZaria, NigeriaContact: Eunice JiyaTaking people
About the trial
What the trial wants to find out
Tuberculosis (TB) is caused by mycobacterial organism. It is the leading infectious disease cause of death globally. According to recent estimates from the World Health Organization (WHO), over 10 million new cases and 1.6 million deaths from TB occurred in 2021. The vast majority of TB cases and TB deaths are in developing countries. Nigeria has the highest TB burden in Africa with a high number of undetected TB cases as well. The spread of HIV has fueled the TB epidemic, and TB is the leading cause of death among patients infected with HIV and has assumed the lead position as the number one infectious disease cause of death globally. Even though the COVID-19 was associated with a huge mortality, TB contributed significantly to death and one of the single predictors of death among COVID-19 infected individuals. TB predominantly affects young adults in their most productive years of life and has substantial impact on economic development.
Read full original descriptionShow less
Emerging evidence has shown that lipid lowering drugs like statins can make the TB bacteria more susceptible to current treatment regimen. The ATORTUB group recently completed Phase II A and Phase IIB studies to assess the safety, tolerability and efficacy of atorvastatin when administered with the current standard of care. The investigators demonstrated that atorvastatin is well tolerated, save, and has beneficial microbiological and radiological impacts in tuberculosis, thus, warrants further studies.
This phase IIC trial sets out to evaluate the safety and efficacy of different doses of atorvastatin containing regimen, determine rate of decline of viable sputum bacilli, the time to stable sputum conversion, improvement in chest ray severity scores and lung function parameters post randomization in the different treatment arms. The phase II C is a Selection Trial with Extended follow-up STEP and has been devised as a pilot phase III where patients are studied for longer period (12months post randomization) than the usual phase IIB. Thus, providing additional data that will justify a successful phase III trial.
The 4 groups in the trial
- 20mg atorvastatin with standard of care (SOC) for TBTreatment being tested
Trial of 20mg atorvastatin with standard of care (SOC) for TB
Treatment: Atorvastatin 20mg
- 40mg atorvastatin with standard of care (SOC) for TBTreatment being tested
Trial of 40mg atorvastatin with standard of care (SOC) for TB
Treatment: Atorvastatin 40mg
- 60mg atorvastatin with standard of care (SOC) for TBTreatment being tested
Trial of 60mg atorvastatin with standard of care (SOC) for TB
Treatment: Atorvastatin 60mg
- Standard of care (SOC) for TBExisting treatment, for comparison
Treatment: Fixed dose combination of Rifampicin (R) Isoniazid (H) Pyrazinamide (Z) Ethambutol (E)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Atorvastatin-containing Treatment Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled phase2C/3 Clinical Trial
- Plain-language title
- Tests atorvastatin with standard drugs in people with pulmonary tuberculosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06199921, who can take part
- Record updated
- 25 September 2025